STOCK TITAN

Clearmind Medicine’s PTSD patent bid published in Hong Kong

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) announced a Hong Kong patent application publication covering psychedelic compounds targeting PTSD and other mental health disorders. The application is part of an exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem; Clearmind says it holds exclusive global rights to develop, manufacture and commercialize the compounds. Its intellectual-property portfolio includes 19 patent families and 32 granted patents.

Heimdall Insights estimated the global PTSD therapeutics market at approximately $19 billion in 2025 and projects $24.8 billion by 2030, with an approximately 5.5% CAGR. Separately, GlobalData projects the PTSD pharmaceutical market across seven major markets will grow from $1.2 billion in 2024 to $5.5 billion by 2034, at a 16.1% CAGR.

Filing Explained

The 6-K incorporates the release’s first four paragraphs into the listed Form F-3 and Form S-8 registration statements effective November 19, 2026, adding those disclosures to the registration-statement record.

Patent families 19 Clearmind's intellectual-property portfolio
Granted patents 32 Included in Clearmind's intellectual-property portfolio
Global PTSD therapeutics market Approximately $19 billion Heimdall Insights estimate for 2025
Global PTSD therapeutics market $24.8 billion Heimdall Insights projection for 2030
Compound annual growth rate Approximately 5.5% Heimdall Insights projection for the global PTSD therapeutics market
PTSD pharmaceutical market across seven major markets $1.2 billion GlobalData projection baseline for 2024
PTSD pharmaceutical market across seven major markets $5.5 billion GlobalData projection for 2034
Compound annual growth rate 16.1% GlobalData projection for the PTSD pharmaceutical market across seven major markets
Post-Traumatic Stress Disorder medical
"compounds targeting the treatment of Post-Traumatic Stress Disorder"
A mental health condition that can develop after a person experiences or witnesses a traumatic event, causing persistent symptoms such as intrusive memories, heightened stress reactions, avoidance of reminders, and trouble sleeping or concentrating. For investors it matters because it can reduce employee productivity, increase healthcare and disability costs, alter consumer behavior, and create demand for treatment and support services—think of a business whose systems keep freezing after a shock, requiring ongoing fixes and higher operating costs.
neuroplastogens medical
"non-hallucinogenic psychedelic-derived neuroplastogens"
Neuroplastogens are drugs or molecules designed to boost the brain’s ability to reorganize and form new connections—think of them as medicines that help the brain ‘rewire’ itself after damage or during therapy. Investors watch them because successful neuroplastogens could become treatments for conditions like depression, Alzheimer’s, or brain injury, creating large markets and sharp changes in company value as trials, approvals, or setbacks occur.
compound annual growth rate (CAGR) financial
"representing a compound annual growth rate (CAGR) of approximately 5.5%"
Compound annual growth rate (CAGR) shows how much an investment grows, on average, each year over a certain period. It’s like measuring how fast a plant grows each year, smoothing out the ups and downs to see the overall growth trend. Investors use CAGR to compare different investments and see which one has the best long-term performance.
exclusive worldwide licensing agreement technical
"part of the Company's exclusive worldwide licensing agreement with Yissum"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many patent families and granted patents does CMND have?

Clearmind says its intellectual-property portfolio includes 19 patent families, including 32 granted patents. The company intends to seek additional patents for its compounds whenever warranted.

Who invented the compounds covered by CMND's Hong Kong patent application?

The compounds were invented by Professors Ahmed Masaewa, Rami Yaka and Avi Priel of the Hebrew University.

Has CMND's Hong Kong patent application resulted in a granted patent?

The announcement concerns a published patent application, and Clearmind says it cannot assure that a patent will issue or, if issued, that it will issue in a form advantageous to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: November 2026

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on November 19, 2026, titled “Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication.”

 

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press release titled: “Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Clearmind Medicine, Inc.
  (Registrant)
     
Date: November 19, 2026 By: /s/ Adi Zuloff-Shani
  Name:  Adi Zuloff-Shani
  Title: Chief Executive Officer

 

 

3

 

 

Exhibit 99.1

 

Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication

 

Vancouver, Canada, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.

 

The patent application is part of the Company’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.

 

The Hong Kong patent publication expands Clearmind’s global patent application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application supports the Company’s strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.

 

According to market research by Heimdall Insights, the global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to reach $24.8 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 5.5%. In addition, GlobalData projects that the PTSD pharmaceutical market across seven major markets is projected to grow from $1.2 billion in 2024 to $5.5 billion by 2034, at a CAGR of 16.1%, reflecting anticipated demand for innovative treatment options.

 

About Clearmind Medicine Inc.

 

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

 

The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

 

 

 

 

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

 

For further information, visit: https://www.clearmindmedicine.com or contact:

 

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

 

Forward-Looking Statements:

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of the novel compounds covered by the patent application; the Company’s ability to develop, manufacture, and commercialize such compounds; the potential commercial opportunities associated with such compounds; the Company’s strategy to seek intellectual property protection for its novel therapeutic candidates across key global markets; and expected growth in the PTSD pharmaceutical market. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

 

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading